| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 32% | Barclays | $32 → $29 | Maintains | Overweight |
| 08/10/2023 | 36.55% | Northland Capital Markets | $35 → $30 | Maintains | Outperform |
| 08/10/2023 | -8.97% | Roth MKM | $30 → $20 | Downgrades | Buy → Neutral |
| 08/10/2023 | 59.31% | Rosenblatt | $45 → $35 | Maintains | Buy |
| 08/10/2023 | 32% | Barclays | $32 → $29 | Maintains | Overweight |
| 05/11/2023 | 59.31% | Oppenheimer | $40 → $35 | Maintains | Outperform |
| 05/11/2023 | 36.55% | Roth MKM | $40 → $30 | Maintains | Buy |
| 05/11/2023 | 36.55% | TD Cowen | $40 → $30 | Maintains | Outperform |
| 05/11/2023 | 45.65% | Barclays | $41 → $32 | Maintains | Overweight |
| 02/17/2023 | 86.62% | Barclays | $35 → $41 | Maintains | Overweight |
| 02/16/2023 | 82.07% | Cowen & Co. | $30 → $40 | Maintains | Outperform |
| 02/16/2023 | 104.82% | Rosenblatt | → $45 | Reiterates | → Buy |
| 02/14/2023 | 104.82% | Rosenblatt | → $45 | Reiterates | → Buy |
| 11/11/2022 | 59.31% | Barclays | $49 → $35 | Maintains | Overweight |
| 11/10/2022 | 104.82% | Rosenblatt | $60 → $45 | Maintains | Buy |
| 02/16/2022 | 173.1% | Rosenblatt | $50 → $60 | Upgrades | Neutral → Buy |
| 06/23/2021 | 127.58% | Rosenblatt | → $50 | Initiates Coverage On | → Neutral |
| 05/11/2021 | 154.89% | Barclays | $64 → $56 | Upgrades | Equal-Weight → Overweight |
| 05/11/2021 | 164% | Northland Capital Markets | $78 → $58 | Upgrades | Market Perform → Outperform |
| 02/17/2021 | 355.17% | Roth Capital | $60 → $100 | Maintains | Buy |
| 09/21/2020 | 118.48% | Northland Capital Markets | $37 → $48 | Upgrades | Market Perform → Outperform |
| 03/30/2020 | — | Northland Capital Markets | Upgrades | Market Perform → Outperform | |
| 08/09/2019 | 59.31% | Canaccord Genuity | $30 → $35 | Maintains | Buy |
| 04/17/2019 | — | Exane BNP Paribas | Downgrades | Outperform → Neutral | |
| 02/14/2019 | — | Northland Capital Markets | Downgrades | Outperform → Market Perform | |
| 10/16/2018 | 82.07% | Canaccord Genuity | $36 → $40 | Maintains | Buy |
What is the target price for CEVA (CEVA)?
The latest price target for CEVA (NASDAQ: CEVA) was reported by Barclays on August 11, 2023. The analyst firm set a price target for $29.00 expecting CEVA to rise to within 12 months (a possible 32.00% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CEVA (CEVA)?
The latest analyst rating for CEVA (NASDAQ: CEVA) was provided by Barclays, and CEVA maintained their overweight rating.
When is the next analyst rating going to be posted or updated for CEVA (CEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CEVA, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CEVA was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating CEVA (CEVA) correct?
While ratings are subjective and will change, the latest CEVA (CEVA) rating was a maintained with a price target of $32.00 to $29.00. The current price CEVA (CEVA) is trading at is $21.97, which is out of the analyst's predicted range.